Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen, in collaboration with Eisai, is currently awaiting a crucial decision from the European Commission regarding the marketing approval of its Alzheimer's drug, Leqembi (lecanemab), aimed at treating early Alzheimer's disease. This development comes on the heels of the European Medicines Agency's Committee providing a positive opinion in November 2024;...

Biogen Awaits European Approval for Alzheimer's Drug Leqembi Amid Reassessment and Growing Sales Potential

As Biogen awaits a pivotal decision from the European Commission on its Alzheimer's drug Leqembi, the stakes are high amid reassessments and promising sales figures. Can this innovative treatment reshape the landscape of Alzheimer's care while navigating regulatory challenges?